UnitedHealthcare expanded its medical policy for Vericel’s MACI® autologous cultured chondrocytes on porcine collagen membrane to include coverage for patients with symptomatic full-thickness cartilage defects in the patella and multiple cartilage defects in the knee.
UnitedHealthcare is the largest commercial payor in the U.S., covering more than 26 million lives. More patients treated with MACI are covered by UnitedHealthcare than any other plan in the U.S.
“We are very pleased that United Healthcare has expanded MACI coverage to include patients with patella and multiple cartilage defects in the knee, which is consistent with the MACI label and current clinical practice,” said Nick Colangelo, President and CEO of Vericel. “Since its launch, MACI has become a preferred treatment option, particularly for patients with cartilage defects on the patella, and this updated policy will increase patient access and support continued MACI growth in the years ahead.”
UnitedHealthcare expanded its medical policy for Vericel's MACI® autologous cultured chondrocytes on porcine collagen membrane to include coverage for patients with symptomatic full-thickness cartilage defects in the patella and multiple cartilage defects in the knee.
UnitedHealthcare is the largest commercial payor in the U.S., covering...
UnitedHealthcare expanded its medical policy for Vericel’s MACI® autologous cultured chondrocytes on porcine collagen membrane to include coverage for patients with symptomatic full-thickness cartilage defects in the patella and multiple cartilage defects in the knee.
UnitedHealthcare is the largest commercial payor in the U.S., covering more than 26 million lives. More patients treated with MACI are covered by UnitedHealthcare than any other plan in the U.S.
“We are very pleased that United Healthcare has expanded MACI coverage to include patients with patella and multiple cartilage defects in the knee, which is consistent with the MACI label and current clinical practice,” said Nick Colangelo, President and CEO of Vericel. “Since its launch, MACI has become a preferred treatment option, particularly for patients with cartilage defects on the patella, and this updated policy will increase patient access and support continued MACI growth in the years ahead.”
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
